RecruitingNCT06068335
Innate Immunity in Allergic Asthma
Sponsor
University of Central Florida
Enrollment
100 participants
Start Date
Oct 18, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Participants must be at least 18 years of age
- no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma.
Exclusion Criteria2
- Pregnant women and prisoners will be excluded from the study.
- Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06068335
Related Trials
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267393 locations
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619138 locations
To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong
NCT046397911 location
Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.
NCT061960342 locations
Use of Biologics for Severe Asthma in Hong Kong
NCT067787461 location